The Expression of Insulin-Like Growth Factor 2 Messenger RNA-Binding Protein 3 in Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma
| Autor: | Hirona Maeda, Tetsurou Yamamoto, Hironori Haga, Tetsuya Tabata, Hirokazu Nakamine, Tatsuki R. Kataoka, Kazuo Ono, Ichiro Murakami, Marina Oji-Tsujimura, Yo Kaku, Yusuke Takei, Konomi Yashige, Yosuke Yamada, Koki Moriyoshi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Langerhans cell Adolescent medicine.medical_treatment General Biochemistry Genetics and Molecular Biology Diagnosis Differential Young Adult Langerhans cell histiocytosis Biomarkers Tumor medicine Humans Neoplasm Child biology business.industry Growth factor Infant Newborn Infant RNA-Binding Proteins Cancer General Medicine Middle Aged medicine.disease Immunohistochemistry Histiocytosis Langerhans-Cell medicine.anatomical_structure Child Preschool Insulin-like growth factor 2 biology.protein Langerhans cell sarcoma Female business Biomarkers Langerhans Cell Sarcoma |
| Zdroj: | The Tohoku Journal of Experimental Medicine. 255:27-31 |
| ISSN: | 1349-3329 0040-8727 |
| DOI: | 10.1620/tjem.255.27 |
| Popis: | Langerhans cell neoplasms, which include Langerhans cell histiocytosis and Langerhans cell sarcoma, are tumors that originate from dendritic cells. Langerhans cell sarcoma is defined as a high-grade neoplasm with overtly malignant cytological features and the Langerhans cell-like phenotype, and generally has a poorer prognosis and more aggressive phenotype than Langerhans cell histiocytosis. Insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types; its expression is often associated with a poor prognosis and aggressive phenotype. Here, we used immunohistochemistry to evaluate IGF2BP3 expression in Langerhans cell neoplasms. IGF2BP3 expression was scored as negative (< 1%) or positive (≥ 1%) by immunohistochemistry. All 4 patients with Langerhans cell sarcoma (100%) and 6 of 22 pediatric (age < 18 years) patients with Langerhans cell histiocytosis (27.3%) had positive results for IGF2BP3; however, 16 of 22 pediatric patients with Langerhans cell histiocytosis (72.7%) and all 15 adult (age ≥ 18 years) patients with Langerhans cell histiocytosis (100%) had a negative result. Among patients with Langerhans cell histiocytosis, IGF2BP3 expression was independent of sex, location, prognosis, and BRAF V600E staining results. Taken together, these results indicate that IGF2BP3 expression may be a helpful marker for distinguishing Langerhans cell sarcoma from Langerhans cell histiocytosis in adult patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|